ND Industries Integration And HHC Pricing Will Secure Stability

Analysts have made a small, valuation-driven adjustment to their view on H.B. Fuller, with the blended price target holding close to prior levels as updated models reflect a slightly lower discount rate, largely stable fair value at about $70, and balanced input from recent upgrades and price target revisions across the Street.

Analyst Commentary

Recent commentary on H.B. Fuller centers on how potential corporate actions and updated models could influence the stock’s risk and reward profile, with JPMorgan’s upgrade and various price target changes framing a mixed but valuation conscious view.

Bullish Takeaways

• JPMorgan’s move to upgrade H.B. Fuller to Neutral from Underweight signals that at least one major firm now sees the risk and reward trade off as more balanced than before, which some investors may read as a reduced downside skew at current levels.
• Bullish analysts point to valuation as a key support, suggesting that the current share price is closer to what their models view as fair, especially as the blended fair value estimate stays in the area of about US$70.
• Positive research updates, including upgrades and some higher price targets, indicate that a portion of the Street is more open to constructive scenarios around execution and capital allocation, particularly around potential transactions.
• The focus on a relatively stable fair value range suggests that longer term growth assumptions in analyst models have not been materially reset, which some investors may interpret as confidence in H.B. Fuller’s underlying business profile.

Bearish Takeaways

• JPMorgan highlights that near term share price performance for H.B. Fuller may hinge on uncertain outcomes, such as whether the company proceeds with the Advanced Medical Solutions transaction or instead pursues a full review of alternatives, which adds execution risk.
• Bearish analysts who have lowered price targets emphasize that there are still questions around how any potential deal or portfolio review would affect leverage, integration risk, and future cash flow, which can weigh on valuation multiples.
• The presence of both price target raises and cuts in a short window points to a divided view on H.B. Fuller’s near term growth and execution, which may limit conviction for some investors even if the average fair value stays relatively steady.
• Recent reductions in price targets from some firms, including Citi and UBS, underline that parts of the Street remain cautious on how quickly any corporate actions or operational adjustments could translate into improved financial metrics.

What’s in the News for H.B. Fuller

• Ancora Holdings LLC publicly urged H.B. Fuller on May 29, 2026 to abandon its pursuit of British medical supplier Advanced Medical Solutions Group plc and instead launch a strategic review following speculation about acquisition interest in H.B. Fuller, source: Activist communication.
• On May 26, 2026, Ancora Holdings Group, LLC released a letter to H.B. Fuller strongly opposing any acquisition of Advanced Medical Solutions Group plc or other businesses, citing concerns about higher leverage above 4.0x net debt to proforma adjusted EBITDA, integration challenges, and the company’s previously stated focus on deleveraging, source: Activist communication.
• H.B. Fuller announced a new Aerospace Manufacturing Center of Excellence in Charlotte, North Carolina, described as a certified manufacturing and innovation facility intended to support aviation, space, and defense customers and align with Project Quantum Leap. The company plans to seek AS9100 and Nadcap accreditations, source: Business expansion disclosure.
• The company reported that between November 30, 2025 and February 28, 2026 it repurchased 0 shares for US$0 under its existing buyback, while total repurchases under the April 7, 2022 authorization reached 1,384,937 shares, or 2.54%, for US$88.74 million, source: Buyback update.
• H.B. Fuller issued earnings guidance indicating full year fiscal 2026 net revenue is expected to be up mid single digits and second quarter 2026 net revenue is expected to be up low single digits, source: Corporate guidance.

Valuation Changes for H.B. Fuller Stock

• Fair Value: Modeled fair value remains steady at about $70.43, indicating no change in the central valuation estimate.
• Discount Rate: The discount rate has fallen slightly from 8.34% to about 8.30%, a modest adjustment that marginally increases the present value of projected cash flows.
• Revenue Growth: The assumed long term revenue growth rate is essentially unchanged, edging from 4.45% to about 4.44% in the latest model.
• Net Profit Margin: The net profit margin assumption has risen very slightly, remaining effectively at about 6.19%, reflecting a minimal adjustment in expected profitability levels used in the H.B. Fuller valuation work.
• Future P/E: The future P/E multiple is broadly stable, moving fractionally from 20.59x to about 20.56x in the updated assumptions.